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Depression has been shown to be associated with cognitive de�cits in various cognitive domains. However, it is still unclear which
factors contribute to cognitive impairment. e objective of this study was to �nd out whether a functional polymorphism in the
promoter region of the serotonin transporter (5-HTTLPR) gene is associated with the impairment of cognitive functioning among
depressed patients. In a pilot study, a sample of 19 patients with major depressive disorder (MDD) and 19 healthy controls was
investigated with an extensive psychiatric and neuropsychological examination. All participants were genotyped for 5-HTTLPR.
Depressed patients with the short allele of the 5-HTT promoter region exhibited inferior cognitive performance compared to
patients with the long allele polymorphism. In healthy controls, no association between genotype and cognitive performance was
found.e result suggests that inMDDpatients with the short allele of the 5-HTTLPR polymorphism the vulnerability to cognitive
impairment is increased compared to MDD patients without the short allele inheritance. ese preliminary �ndings need to be
con�rmed in a larger cohort of MDD patients.
1. Introduction
It is well established that patients with depression are subject
to multiple cognitive de�cits. e impairments have been
found in a broad range of neuropsychological tests and
in various cognitive domains, such as executive functions,
psychomotor speed, and episodic memory [1]. Impairment
may occur in patients under medication as well as in drug-
free patients [2], in younger or elderly patients [3, 4] or
in diﬀerent depression severity levels or subtypes. Some
of these de�cits may persist even upon clinical recovery
[5]. Most importantly, not all of the depressed patients
show deterioration in cognitive capabilities, that is, some
patients seem to be more vulnerable to impairment than
others. e complex relationship between neurocognitive
function and mood may partly be the result of interaction
between the serotonergic system and the corticolimbic neural
circuits of these processes [6]. Growing literature indicates
the importance of the serotonin transporter gene (SLC6A4),
which codes for the serotonin transporter protein (5-HTT),
in the development and integrity of neural systems that sub-
serve emotional regulation [7]. Recent research has provided
important insights into the role of genetic variation in the
SLC6A4-linked polymorphic region (5-HTTLPR) on neural
systems subserving anxiety and depression.e short variant
of the 5-HTTLPR of SLC6A4 (S) has been associated with
traits related to anxiety and depression [8]. e short variant
S has also been reported being associated with susceptibility
to depression in response to stressful life events [9] and
in response to increased stress sensitivity in the childhood
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maltreatment [10]. It has been suggested that the 5-HTT
gene might also be involved in social behavior [11]. Whether
5-HTTLPR exacerbates cognitive impairment in association
with depression is still unknown. It has been shown that
the 5-HTTLPR polymorphism has an eﬀect on hippocampal
volumes of depressed patients, which is apparent only in S/S
genotype [12]. It has also been implied that major depressive
disorder (MDD) could serve as a risk factor for developing
Alzheimer’s disease [13]. On the other hand, there is some
evidence of better cognitive performance among healthy
individuals possessing a copy of the short variant of the
polymorphism compared with individuals homozygous for
the long variant [14, 15]. e evidence concerning the role of
5-HTT in depression-related cognitive functioning is sparse.
In our naturalistic sample of patients withMDD, the aim was
to �nd out whether variation in the serotonin transporter
gene moderates the in�uence of depression on cognitive
impairment.
2. Methods
2.1. Participants. Nineteen inpatients, who met DSM-IV
criteria for major depressive disorder (MDD), were recruited
from the Department of Psychiatry of the Helsinki Univer-
sity Central Hospital. We included patients with a current
moderate or severe episode of MDD with a minimum score
of 18 points on the Hamilton Rating Scale for Depression
(HDRS, 21 items) [16]. Diagnoses were made using the
Structured Clinical Interview for DSM-IV Axes I and II
Disorders (SCID-I and SCID-II) [17, 18]. Exclusion criteria
were current or past neurological disorders (except for occa-
sional migraine attacks), drug- and/or alcohol-dependence
disorderswithin the last �ve years, and overt psychosis during
the study. All patients were on antidepressant medication;
of these, only eight patients with one antidepressant only.
Although the patients were primarily on selective serotonin
reuptake inhibitor (such as �uoxetine) or on serotonin
and norepinephrine reuptake inhibitor (such as venlafax-
ine) medication, sedative antidepressant medication (such
as mirtazapine or mianserin) was also used. Prescriptions
of additional psychiatric drugs (such as antipsychotics for
mood or sleep and mood stabilizer for pain) were in regular
use for some of the patients. Six patients were habitual
smokers, smoking daily or almost daily. Nineteen healthy
volunteers, serving as control subjects and recruited by �yers
from various locations, such as educational communities,
schools, and business companies, were free from current or
past neurological, mental, and alcohol-dependence disorders
and were not on psychotropic medication, neither did their
�rst-degree relatives have a history of mental illness. All
participants were Caucasian. e study was approved by the
Ethics Committee of the Department of Psychiatry, Helsinki
University Central Hospital. Written informed consent was
obtained from all participants.
2.2. Genotyping. 5-HTTLPR (SLC6A4, 44-BP INS/DEL) was
analyzed of the subjects’ DNA extracted from peripherally
drawn venous blood samples (Puregene, Gentra systems,
Minneapolis, MN, USA). e SLC6A4 promoter region
containing the long (16A)/short (14A) (L/S) polymorphism
was PCR-ampli�ed using the following primers� forward 5�-
CGC TCC TGC ATC CCC CAT TA-3� and reverse 5�-
GGG ATG CGG GGG AAT ACT GGT-3�, which produced
297/253 bp (L/S) product. e genotype was analyzed by 3%
MetaPhor (R) agarose (FMC BioProducts, Rockland, ME,
USA) gel electrophoresis. Genotypic testing was conducted
blindly to clinical and neuropsychological results. Since the
SS and SL seem to have similar functional consequences on
5-HTT activity [8], SS and SL genotypes were combined into
one group (S variant) and compared with the LL genotype (L
variant).
2.3. Measures
2.3.1. Self-Ratings. All participants were administered print-
ed versions of the Beck Depression Inventory-II [19], the
Hopelessness Scale [20], and the Beck Anxiety Inventory
[21] as a self-report instrument to determine the pres-
ence and severity of depression, hopelessness, and anxiety
symptoms.
2.3.2. Neuropsychological Tests. An approximately 2-hour
battery of 16 neuropsychological tests with standard instruc-
tions [22] was administered to all participants at 8 or 10
o’clock in the morning. e neuropsychological examination
was conducted blindly to genotyping results and covered �ve
speci�c cognitive domains. Verbal reasoning was evaluated
with the similarities and nonverbal reasoning with the block
design subtests of the Wechsler Adult Intelligence Scale-
Revised (WAIS-R) [23]. Immediate and delayed episodic
memory was assessed by the Logical Memory I and II, Verbal
Paired Associates I and II, and Visual Reproduction I and II
subtests of the Wechsler Memory Scale-Revised (WMS-R)
[24]. Working memory was measured by the Visual Memory
Span (forwards and backwards) and the Letter-Number
Sequencing (WMS-III) [25]. e domain of attention and
executive functioning was assessed with the Trail Making Test
Part B [26], the color-word interference part of the Stroop
test, and with verbal �uency both in semantic (animals)
and phonological category (words beginning with the letter
S) in 60 seconds. Processing and motor speed was assessed
with the Trail Making Test Part A, the color-naming task in
the Stroop test, and the Digit Symbol subtest of the WAIS-
R. In addition, the simple motor speed of the right and
le thumbs in 10 seconds was assessed using the Finger
Tapping Test (FTT). While patients with depression are
subject to multiple neuropsychological de�cits, our attempt
was to catch this heterogeneity by also calculating the number
of impaired performances in the cognitive tests to indicate
overall impairment. e impairment was de�ned as the
number of neuropsychological test variables with at least −1
standard deviation (SD) compared with the controls’ mean
performance.
2.4. Statistical Analysis. e diﬀerences between demo-
graphic, clinical, and neuropsychological characteristics of
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the study groups were examined with the 𝜒𝜒2 test, the
independent samples 𝑡𝑡-test, and MANCOVA age and gender
as covariates. Due to a small sample size and violation
of normality in sample distribution, the eﬀect of the 5-
HTTLPR variant on the neurocognitive performance was
analyzed using permutational (nonparametric) MANCOVA
[27, 28] gender and age as covariates. Results of permuta-
tional MANCOVA were further examined using individual
permutational ANCOVA as proposed by Manly [29]. All
permutational analysis was analyzed using R version 12.1
statistical environment [30] and especially permutational
MANCOVA using R function Adonis in the vegan package
[31]. Poisson regression [32] with the Wald chi-square
statistic was examined to compare the number of impaired
neuropsychological test performances related to 5-HTTLPR
variants and MDD and control group interaction.
3. Results
Our MDD group consisted of participants with the history
of recurrent depression, with the mean duration of illness
being eight years.e distribution of the 5-HTTLPR variants
did not diﬀer between the patient and control groups (Table
1). Among the MDD group, 63.2% of the patients were
carrying the S variant (SL or SS genotype) and 36.8% the
L variant, and among controls the frequencies of S and L
alleles were 68.4% and 31.6%, respectively. As shown in
Table 1, the groups did not diﬀer in terms of age, gender,
or education. Overall, the MANCOVA showed signi�cant
group eﬀect for the neuropsychological measures when age
and gender were covariates (Wilks 𝜆𝜆 𝜆 𝜆𝜆2𝜆, 𝐹𝐹(19,27), 𝑃𝑃 𝜆
𝜆𝜆𝜆2, 𝜂𝜂2partial 𝜆 𝜆𝜆𝜆7). Univariate comparisons revealed that
MDD group scored lower than controls on the domains
which represent nonverbal (visuospatial) reasoning, verbal
and visual episodic memory and on the tests measuring
processing and motor speed. No diﬀerences were found on
the domains of working memory and executive functions.
To �nd out the association of the allele of the 5-HTT
promoter polymorphism in depression and neurocognitive
performance, we compared the interaction of the group
(MDD and controls) and 5-HTTLPR variants and the
neuropsychological test performances. e permutational
MANCOVA revealed signi�cant group � variant interaction
in neuropsychological test results, when gender and age were
covariates (𝐹𝐹(1,19) 𝜆 3𝜆28, 𝑃𝑃 𝜆 𝜆𝜆𝜆1, 𝜂𝜂2partial 𝜆 𝜆𝜆17). ere was
also signi�cant group main eﬀect (𝐹𝐹(1,19) 𝜆 2𝜆𝜆9, 𝑃𝑃 𝜆 𝜆𝜆𝜆𝜆,
𝜂𝜂2partial 𝜆 𝜆𝜆13).
Permutational univariate comparisons (ANCOVAS) re-
vealed that in the MDD group, the subjects with S allele
scored lower in the tests of the block design (𝑃𝑃 𝜆 𝜆𝜆𝜆𝜆) and in
the LogicalMemory II (the𝑃𝑃 value for the interaction = 0.02).
Almost signi�cant result was reached in the Logical Memory
I (𝑃𝑃 𝜆 𝜆𝜆𝜆7) and in the semantic �uency (𝑃𝑃 𝜆 𝜆𝜆𝜆8).
We also conducted Poisson regression analysis, con-
trolling for gender and age, to compare the number of
impaired neuropsychological test performances related to 5-



























F 1: Number of impaired neuropsychological test perfor-
mances in major depressive disorder (MDD) patients and controls
carrying the S variant and the L variant of the 5-HTTLPR.
It was found out that the mean number of impaired test
performances was almost signi�cantly (𝜒𝜒2(1) 𝜆 3𝜆𝜆𝜆, 𝑃𝑃 𝜆
𝜆𝜆81) higher in S allele carriers in the MDD group compared
to controls, whereas there was no diﬀerence in L carriers
between groups (Figure 1). ere was also signi�cant group
main eﬀect (𝜒𝜒2(1) 𝜆 15𝜆𝜆3, 𝑃𝑃 𝑃 𝜆𝜆𝜆𝜆1).
In theMDD group, the patients carrying the S variant did
not diﬀer from those carrying the L variant of the 5-HTTLPR
in terms of the duration of the illness, number of depressive
episodes, HDRS, BDI, BHS, or BAI. No signi�cant Spearman
rho correlations were found between the number of impaired
neuropsychological test performances and the duration of the
illness, the number of depressive episodes, HDRS, BDI, BHS,
or BAI.
4. Discussion
Along with aﬀective disturbances, cognitive impairment is
usually one of the key dimensions in major depression.
Our study was composed to �nd out whether depression-
related neurocognitive impairment is associated with the
variation in the serotonin transporter gene. As expected, the
MDD group scored lower than the healthy controls on sev-
eral cognitive domains representing visuospatial reasoning,
episodic memory as well as processing and motor speed.
Most importantly, we found out that cognitive impairment in
verbal episodic memory as well as in visuospatial reasoning
was associated with the short variant of the 5-HTT promoter
polymorphism among patients with MDD. In addition, there
was a trend showing that the overall number of impaired
test performances was higher in S allele carriers in the
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(𝑛𝑛 𝑛 𝑛𝑛) Statistics 𝑃𝑃 value
Eﬀect size
(Cohen’s 𝑑𝑑)
5-HTTLPR S/L allele 12/7 13/6 𝜒𝜒2 𝑛 0.𝑛2 0.732
Gender, female/male 15/4 14/5 𝜒𝜒2 𝑛 0.𝑛5 0.703
Age, years (range 18–56) 34.8 (12.7) 36.0 (15.8) 𝑡𝑡 𝑛 𝑡2.𝑡0 0.797 0.08
Education, years 13.4 (2.4) 14.7 (2.8) 𝑡𝑡 𝑛 𝑡𝑛.𝑡𝑡 0.150 0.50
Duration of illness, years (range) 8.1 (8.0) —
Number of depressive episodes 2.3 (1.6) —
Self-ratings:
HDRS 24.0 (3.7) —
BDI total score, range 0–60 32.6 (11.8) 1.2 (1.6) 𝑡𝑡 𝑛 𝑛𝑛.𝑡𝑡 <0.001 4.69
BHS total score, range 0–63 12.5 (5.0) 1.9 (0.9) 𝑡𝑡 𝑛 𝑛.0𝑡 <0.001 3.59
BAI total score, range 0–20 19.5 (10.6) 1.9 (1.2) 𝑡𝑡 𝑛 𝑛𝑛.𝑡𝑡 <0.001 2.98
Neuropsychological tests:
Abstract reasoning
Similarities 26.8 (3.7) 27.3 (3.0) 𝐹𝐹 𝑛 0.𝑛5 0.700 0.15
Block design 34.5 (7.6) 39.5 (8.6) 𝐹𝐹 𝑛 5.𝑛𝑛 0.029 0.62
Episodic memory
Logical memory I 22.3 (8.6) 27.4 (5.4) 𝐹𝐹 𝑛 𝑡.𝑡𝑛 0.037 0.73
Logical memory II 19.7 (8.4) 25.0 (4.9) 𝐹𝐹 𝑛 5.2𝑡 0.028 0.80
Verbal paired associates I 18.6 (4.7) 20.7 (2.6) 𝐹𝐹 𝑛 𝑡.0𝑡 0.089 0.58
Verbal paired associates II 6.8 (1.6) 7.4 (0.9) 𝐹𝐹 𝑛 2.𝑡𝑡 0.107 0.48
Visual reproduction I 33.3 (3.7) 38.6 (2.1) 𝐹𝐹 𝑛 𝑡2.0𝑡 <0.001 1.83
Visual reproduction II 32.5 (5.1) 37.7 (2.9) 𝐹𝐹 𝑛 𝑛𝑡.0𝑛 <0.001 1.30
Working memory
Visual memory span 18.3 (2.9) 19.6 (2.4) 𝐹𝐹 𝑛 2.𝑡𝑡 0.133 0.49
Letter number sequencing 10.5 (2.4) 11.3 (2.0) 𝐹𝐹 𝑛 𝑛.20 0.280 0.36
Executive functioning
Trail making test B sec. 74.1 (21.6) 71.3 (26.9) 𝐹𝐹 𝑛 0.𝑛5 0.697 0.12
Stroop color-word sec. 109.5 (21.3) 104.9 (30.2) 𝐹𝐹 𝑛 0.𝑡0 0.587 0.18
Semantic �uency 23.2 (6.3) 26.5 (5.1) 𝐹𝐹 𝑛 𝑡.𝑛𝑡 0.086 0.58
Letter �uency 16.8 (3.9) 18.3 (3.7) 𝐹𝐹 𝑛 𝑛.𝑛𝑡 0.290 0.39
Processing and motor speed
Trail making test A sec. 37.6 (10.8) 31.4 (8.0) 𝐹𝐹 𝑛 5.𝑡𝑡 0.026 3.96
Stroop color naming 73.1 (11.7) 63.5 (10.2) 𝐹𝐹 𝑛 𝑡.0𝑛 0.012 0.88
Digit symbol (WAIS-R) 57.6 (11.9) 63.5 (12.1) 𝐹𝐹 𝑛 𝑡.0𝑡 0.090 0.49
Finger tapping, dominant 47.5 (4.6) 51.1 (6.1) 𝐹𝐹 𝑛 𝑡.𝑛2 0.033 0.67
Finger tapping, nondominant 41.7 (5.1) 45.5 (4.4) 𝐹𝐹 𝑛 5.𝑡𝑛 0.022 0.80
e results are given as mean (SD), except for gender and 5-HTTLPR variants, for which the results are given as frequency. Group comparisons in
neuropsychological tests were analyzed with MANCOVA in which gender and age were covariates.
HDRS: Hamilton Rating Scale for Depression; BDI: Beck’s Depression Inventory; BHS: Beck’s Hopelessness Scale; BAI: Beck’s Anxiety Inventory.
MDD group compared with controls, whereas there was no
such diﬀerence in L carriers between groups. It was notable
that cognitive impairment was not related to the severity of
psychiatric symptoms among the depressed patients. us,
the result suggests that the 5-HTTLPR variation may play
an important role in the modulation of neurocognitive
performance in depression, the short allele being responsible
for some part of the cognitive de�cits seen in depression. To
our knowledge, there are no previous studies examining the
association between 5-HTT allelic variation and depression-
related neurocognition in a real-world psychiatric setting.
Some recent studies, however, support the hypothesis that
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the S allele interacts with stress to negatively impact cognitive
functioning, especially in the older age [33, 34].
e main limitation of our study was the small sam-
ple size; even though we used a powerful candidate gene
approach, our result can only be considered preliminary.
Moreover, the original diallelic L/S analysis that was applied
in our study can be criticized because the L allele can be
subtyped into L(A) and L(G) alleles [35]. However, recent
evidence comparing both diallelic and triallelic approaches
has not found signi�cant diﬀerences between the two subtype
analyses in MDD patients [36]. In future studies, a haplotype
analysis might be a tool for increasing the eﬀectiveness of
evaluation of the association we found [37].
e additional limitations of our study aremostly derived
from the naturalistic study design. First, the patients were on
several medications. Although we acknowledge that sedative
psychoactive drugs may modulate neuropsychological test
performances, the potential cognitive eﬀects of these drugs
could not be reliably analyzed because of the small sample
size and various combinations of medication. Second, we
had too few male patients to be able to analyze both genders
separately, and thus our result cannot be generalized to both
sexes without future studies of male patients. Genetic factors
may play a greater role in the etiology ofMDD inwomen than
inmen [38].On the other hand, association between the short
allele and greater reactivity to negative emotional stimuli
has been shown to be independent of gender [39]. ird,
information on possible early life stressors of our participants
was not available.
e strength of our study is an extensive psychiatric
evaluation and detailed neuropsychological test battery,
performed to all participants. In our study, the cognitive
measures were selected to represent the neuropsychological
domains that have been shown to be the most vulnerable to
impairment in depression [1].ismay partly explain the fact
that we were able to reach a signi�cant association between
neurocognitive impairment and the short allele of the 5-HTT
promoter polymorphism even with such a small sample. In
general, a test-taking strategy and response monitoring can
in�uence performance and obscure a genotype association in
a way that may not directly re�ect the underlying neurocog-
nitive de�cit [40].
While depression is not always accompanied by cognitive
impairment, it is important to try to establish the factors
aﬀecting impairment to �nd better strategies for treatment.
Our results support the suggestion according to which the
impact of the 5-HTT gene on behavior might be much
broader than commonly appreciated [11]. Further research
is needed to con�rm our �ndings and to indicate which
neurocognitive subcomponents might be responsible for
mediating neurobiological processes that are in�uenced by
the genetic variation of the serotonin transporter. In future
studies, it would also be worthwhile to further test cognition
impairment related issues, 5-HTT and depression in various
settings, for instance, a hypothesis according to which a
risk to develop Alzheimer’s disease may be increased among
MDD patients with the short variant of 5-HTT, recurrent
depressive episodes and prodromal neurocognitive impair-
ment.
5. Conclusion
e variation in the serotonin transporter gene may play an
important role in the modulation of cognitive performance
in major depression, the MDD patients with the short allele
of the 5-HTTLPR polymorphism being more vulnerable to
cognitive impairment compared with MDD patients without
the short allele inheritance.
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